Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3. This indicates a small update to the page's revision tag.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision label was updated from v3.5.2 to v3.5.3, indicating a minor version change to the site display rather than a change to the clinical trial content.SummaryDifference0.1%

- Check38 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check53 days agoChange DetectedMedullary thyroid carcinoma is now listed as a condition, and the Genetic and Rare Diseases Information Center has been added to the Resources section.SummaryDifference0.2%

- Check67 days agoChange DetectedRevision updated to v3.5.0, replacing v3.4.3.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision: v3.4.3 is shown instead of v3.4.2. There are no visible changes to the study information or user actions on the page.SummaryDifference0.1%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.